Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China
China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co.,...
Company
Novo Nordisk to Invest RMB 400M in Shanghai at CIIE
Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...
Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study
China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...
Hainan Free Trade Port to Simplify Drug Import Procedures
The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...
Sinovac’s Varicella Vaccine Receives WHO Pre-Qualification
China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...
Reforgene Medicine RM-001 Thalassemia Gene Editing
China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...
Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...
Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized,...
Bloomage Biotech CEO Investigated Over Discounted Share Sales
The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao...
Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH
Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...
Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma
China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...
Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials
China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy,...
Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products
Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology...
Yaguo Technology Secures Series A+ Funding for Airway Management Devices
Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...
Novatim Immune Therapeutics Raises RMB 500M in First Financing Round
China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...
Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round
Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...
Akeso Biopharma Completes Enrollment for AK112 Phase III Study
China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...
Eccogene Gains FDA Approval for Phase I Study of ECC5004
Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...